SCHEMBL20162122

SCHEMBL20162122

O=C(Nc1cn(Cc2cc(F)cc(Cl)c2)cn1)c1ccc2c(c1)CCNC2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R8 Q9NYW2 1/20 0.47
PTGER1 P34995 3/20 0.46
WNT1 P04628 6/20 0.45
GSK3B P49841 6/20 0.45
DYRK1A Q13627 6/20 0.45
MELK Q14680 1/20 0.42
SLC2A1 P11166 2/20 0.41
CLK2 P49760 2/20 0.41
CLK3 P49761 2/20 0.41
CYP3A4 P08684 1/20 0.40
MAP3K5 Q99683 1/20 0.39
F2 P00734 1/20 0.39
PLG P00747 1/20 0.39
PLAU P00749 1/20 0.39
PLAT P00750 1/20 0.39
KLKB1 P03952 1/20 0.39
PRSS1 P07477 1/20 0.39
ITGB3 P05106 1/20 0.36
ITGA2B P08514 1/20 0.36
ITGA2 P17301 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20162132 0.95 TAS2R8 (0.49) TAS2R8PTGER1WNT1GSK3BDYRK1A
SCHEMBL20162138 0.89 TAS2R8 (0.46) TAS2R8PTGER1WNT1GSK3BDYRK1A
SCHEMBL20162170 0.89 TAS2R8 (0.46) TAS2R8PTGER1WNT1GSK3BDYRK1A
SCHEMBL20169955 0.89 PTGER1 (0.49) TAS2R8PTGER1WNT1GSK3BDYRK1A
SCHEMBL20162120 0.88 TAS2R8 (0.49) TAS2R8PTGER1WNT1GSK3BDYRK1A
SCHEMBL20162128 0.88 PTGER1 (0.44) TAS2R8PTGER1WNT1GSK3BDYRK1A
SCHEMBL20162143 0.87 TAS2R8 (0.37) TAS2R8PTGER1WNT1GSK3BDYRK1A
SCHEMBL20162131 0.87 TAS2R8 (0.46) TAS2R8PTGER1WNT1GSK3BDYRK1A
SCHEMBL20162178 0.86 TAS2R8 (0.48) TAS2R8PTGER1WNT1GSK3BDYRK1A
SCHEMBL20364396 0.85 WNT1 (0.49) TAS2R8PTGER1WNT1GSK3BDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10294237-B2 Bicyclic heterocyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2019-05-21 US claimed
US-20180194773-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-07-12 US claimed
EP-3323809-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE Sumitomo Dainippon Pharma Co., Ltd. (JP) 2018-05-23 EP claimed
US-10294237-B2 Bicyclic heterocyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2019-05-21 US disclosed
US-20180194773-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-07-12 US disclosed
EP-3323809-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE Sumitomo Dainippon Pharma Co., Ltd. (JP) 2018-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10294237-B2 Bicyclic heterocyclic amide derivative NR0B1, NR2E1, NR0B2 TAS2R8 2479/4885PTGER1 478/4885WNT1 223/4885
US-20180194773-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE NR0B1, NR2E1, NR0B2 TAS2R8 2479/4885PTGER1 478/4885WNT1 223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.